File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Epidermal fatty-acid-binding protein: A new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosis

TitleEpidermal fatty-acid-binding protein: A new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosis
Authors
KeywordsAtherosclerosis
Fatty-acid-binding proteins
Metabolic syndrome
Obesity
Risk factors
Issue Date2008
PublisherOxford University Press. The Journal's web site is located at http://eurheartj.oxfordjournals.org/
Citation
European Heart Journal, 2008, v. 29 n. 17, p. 2156-2163 How to Cite?
AbstractAims: Epidermal fatty-acid-binding protein (E-FABP) is highly homologous to adipocyte FABP (A-FABP), which mediates obesity-related metabolic syndrome (MetS), diabetes and atherosclerosis in animals. Combined deficiency of E-FABP and A-FABP protects against the MetS and atherosclerosis in mice. This study investigated the association of serum E-FABP with cardio-metabolic risk factors and carotid atherosclerosis in humans. Methods and results: The presence of E-FABP in human plasma was detected by tandem mass spectrometry. Serum E-FABP levels, determined by an enzyme-linked immunosorbent assay in 479 Chinese subjects (age: 55.4 ± 13.5 years; M/F: 232/247), correlated positively (P < 0.05 to <0.001, age-adjusted) with parameters of adiposity, adverse lipid profiles, serum insulin, A-FABP, and C-reactive protein levels and were higher in subjects with the MetS (P < 0.001 vs. no MetS). The association of E-FABP with the MetS was independent of A-FABP. Furthermore, serum E-FABP correlated with carotid intima-media thickness (IMT; P < 0.001) and was independently associated with carotid IMT in men (adjusted P = 0.03). Conclusion: E-FABP is a new circulating biomarker associated with increased cardio-metabolic risk. It may contribute to the development of the MetS and carotid atherosclerosis in humans, independent of the effect of A-FABP. © The Author 2008.
Persistent Identifierhttp://hdl.handle.net/10722/59175
ISSN
2014 Impact Factor: 15.203
2014 SCImago Journal Rankings: 5.738
ISI Accession Number ID
Funding AgencyGrant Number
Hong Kong Research Grant CouncilHKU7404/ 04M
7590/06M
Funding Information:

This study was supported by the Hong Kong Research Grant Council (HKU7404/ 04M and 7590/ 06M to K. S. L. L.) and the matching funding for China National 973 basic research project to A. X.

References

 

DC FieldValueLanguage
dc.contributor.authorYeung, DCYen_HK
dc.contributor.authorWang, Yen_HK
dc.contributor.authorXu, Aen_HK
dc.contributor.authorCheung, SCWen_HK
dc.contributor.authorWat, NMSen_HK
dc.contributor.authorFong, DYTen_HK
dc.contributor.authorFong, CHYen_HK
dc.contributor.authorChau, MTen_HK
dc.contributor.authorSham, PCen_HK
dc.contributor.authorLam, KSLen_HK
dc.date.accessioned2010-05-31T03:44:20Z-
dc.date.available2010-05-31T03:44:20Z-
dc.date.issued2008en_HK
dc.identifier.citationEuropean Heart Journal, 2008, v. 29 n. 17, p. 2156-2163en_HK
dc.identifier.issn0195-668Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/59175-
dc.description.abstractAims: Epidermal fatty-acid-binding protein (E-FABP) is highly homologous to adipocyte FABP (A-FABP), which mediates obesity-related metabolic syndrome (MetS), diabetes and atherosclerosis in animals. Combined deficiency of E-FABP and A-FABP protects against the MetS and atherosclerosis in mice. This study investigated the association of serum E-FABP with cardio-metabolic risk factors and carotid atherosclerosis in humans. Methods and results: The presence of E-FABP in human plasma was detected by tandem mass spectrometry. Serum E-FABP levels, determined by an enzyme-linked immunosorbent assay in 479 Chinese subjects (age: 55.4 ± 13.5 years; M/F: 232/247), correlated positively (P < 0.05 to <0.001, age-adjusted) with parameters of adiposity, adverse lipid profiles, serum insulin, A-FABP, and C-reactive protein levels and were higher in subjects with the MetS (P < 0.001 vs. no MetS). The association of E-FABP with the MetS was independent of A-FABP. Furthermore, serum E-FABP correlated with carotid intima-media thickness (IMT; P < 0.001) and was independently associated with carotid IMT in men (adjusted P = 0.03). Conclusion: E-FABP is a new circulating biomarker associated with increased cardio-metabolic risk. It may contribute to the development of the MetS and carotid atherosclerosis in humans, independent of the effect of A-FABP. © The Author 2008.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://eurheartj.oxfordjournals.org/en_HK
dc.relation.ispartofEuropean Heart Journalen_HK
dc.rightsEuropean Heart Journal. Copyright © Oxford University Press.en_HK
dc.subjectAtherosclerosisen_HK
dc.subjectFatty-acid-binding proteinsen_HK
dc.subjectMetabolic syndromeen_HK
dc.subjectObesityen_HK
dc.subjectRisk factorsen_HK
dc.subject.meshAdiposity - physiologyen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshBiological Markers - blooden_HK
dc.subject.meshCarotid Artery Diseases - diagnosisen_HK
dc.subject.meshCarotid Intima-Media Thicknessen_HK
dc.subject.meshFatty Acid-Binding Proteins - blooden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMetabolic Syndrome X - blooden_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshObesity - blooden_HK
dc.subject.meshRisk Factorsen_HK
dc.titleEpidermal fatty-acid-binding protein: A new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosisen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0195-668X&volume=29&spage=2156&epage=63&date=2008&atitle=Epidermal+fatty-acid-binding+protein:+a+new+circulating+biomarker+associated+with+cardio-metabolic+risk+factors+and+carotid+atherosclerosisen_HK
dc.identifier.emailWang, Y: yuwanghk@hku.hken_HK
dc.identifier.emailXu, A: amxu@hkucc.hku.hken_HK
dc.identifier.emailFong, DYT: dytfong@hku.hken_HK
dc.identifier.emailSham, PC: pcsham@hku.hken_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.authorityWang, Y=rp00239en_HK
dc.identifier.authorityXu, A=rp00485en_HK
dc.identifier.authorityFong, DYT=rp00253en_HK
dc.identifier.authoritySham, PC=rp00459en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/eurheartj/ehn295en_HK
dc.identifier.pmid18603624en_HK
dc.identifier.scopuseid_2-s2.0-50849107871en_HK
dc.identifier.hkuros152080en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-50849107871&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume29en_HK
dc.identifier.issue17en_HK
dc.identifier.spage2156en_HK
dc.identifier.epage2163en_HK
dc.identifier.isiWOS:000258862700018-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYeung, DCY=36869426200en_HK
dc.identifier.scopusauthoridWang, Y=34973733700en_HK
dc.identifier.scopusauthoridXu, A=7202655409en_HK
dc.identifier.scopusauthoridCheung, SCW=17533628600en_HK
dc.identifier.scopusauthoridWat, NMS=6602131754en_HK
dc.identifier.scopusauthoridFong, DYT=35261710300en_HK
dc.identifier.scopusauthoridFong, CHY=14033917100en_HK
dc.identifier.scopusauthoridChau, MT=7006073758en_HK
dc.identifier.scopusauthoridSham, PC=34573429300en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats